查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433445

全球E型肝炎診斷測試市場 2023-2030

Global Hepatitis E Diagnostic Tests Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 240 Pages | 商品交期: 2-3個工作天內

價格

全球E型肝炎診斷測試市場預計在預測期內（2024-2031年）CAGR為7.40%。市場的成長歸因於對全球健康關注的需求。E型肝炎作為主要公共衛生問題的全球盛行率和重要性推動了診斷測試的不斷成長和接受，以有效管理和盡量減少疾病對公共衛生的影響。根據美國國立衛生研究院（gov.）2023年5月的資料，E型肝炎是由E型肝炎病毒（HEV）引起的肝臟炎症，通常透過受污染的水或食用未煮熟的動物肉（尤其是豬肉）傳染。根據世界衛生組織（WHO）統計，每年約有 2,000 萬例 HEV 感染，導致 330 萬有症狀病例和 44,000 人死亡。這佔病毒性肝炎相關死亡率的 3.3%。而E型肝炎在全球流行。

細分市場前景

全球E型肝炎診斷測試市場依產品類型、動物類型、應用和最終用戶進行細分。根據產品類型，市場分為固定式多層 CT 掃描儀和攜帶式 CT 掃描儀。根據動物類型，市場分為伴侶動物、牲畜動物和其他動物。根據應用，市場細分為神經病學、腫瘤學、心臟病學、腎臟病學、胃腸病學等。此外，根據最終用戶，市場細分為獸醫診所和醫院、研究機構等。酶聯免疫吸附測定（ELISA）子類別預計將佔據技術領域的很大一部分市場佔有率。該成長可歸因於醫院廣泛採用診斷肝炎的程序。

預計血清學測試細分市場將在全球E型肝炎診斷測試市場中佔據相當大的佔有率

在疾病類型中，血清學檢測子細分市場預計將在全球E型肝炎診斷檢測市場中佔據相當大的佔有率。細分市場的成長歸因於血清學檢測的進步。酵素免疫分析（EIA）測試的引進，特別是能夠識別 IgM 和 IgG 抗 HEV 抗體的被動 EIA 技術，強調了E型肝炎診斷血清學測試的技術進步。 IgM 和 IgG 抗體之間的區分有助於識別現代或先前的疾病。據 MDPI 表示，2021年 1月，用於檢測 HEV 感染的血清學檢測包括酵素免疫分析（EIA）檢測。間接 EIA 測定能夠檢測 IgM 和 IgG 抗 HEV 抗體。 IgM 抗 HEV 抗體最早出現，顯示急性或近期感染，而 IgG 抗 HEV 抗體持續數年，顯示近期或先前感染。然而，這些檢測的靈敏度和特異性可能有所不同，並且可能與其他病毒（如 CMV 和 EBV）發生交叉反應。萬泰試驗是最常用的 IgM 檢測商業 ELISA 試驗，在 EIA 試驗中以其高靈敏度和特異性而聞名。

區域展望

全球E型肝炎診斷測試市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國） 、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於醫療保健設施的不斷成長、適用的製造商數量巨大以及政府參與度和專業社區的增加，預計亞太地區將在全球市場中佔據顯著佔有率。

北美地區預計全球E型肝炎診斷測試市場將以顯著的CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區診斷測試的發展。這些研究的見解推動了診斷測試的發展，這些測試能夠識別E型肝炎感染的多種標記物，例如抗體和病毒RNA，以便提供更完整的診斷圖並幫助了解疾病動態。據 MDPI 表示，2023年 10月，對愛沙尼亞 1002 份供體血清中抗 HEV IgG 和 IgM 抗體以及病毒 RNA 的流行情況進行了分析。其中，48份血清（4.8%）檢測出抗HEV抗體呈陽性，其中40份（4%）含有抗HEV IgG，15份（1.5%）含有抗HEV IgM。此外，7 名捐贈者同時擁有這兩類抗體。然而，在任何血清樣本中均未檢測到 HEV RNA。然而，隨著年齡的成長，抗 HEV IgG 帶因者的發生率較高，統計分析發現感染風險變數與抗 HEV 抗體盛行率之間沒有統計上的顯著關聯。

市場參與者展望

服務於E型肝炎診斷測試市場的主要公司包括 Bio-Rad Laboratories, Inc.、Danaher Corp.、Diasorin SpA、EKF Diagnostics Holdings plc、ELITech Group 等。市場參與者透過各種策略（包括併購、夥伴關係、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2022年9月，Gilead Sciences, Inc.與Brigham婦女醫院、Harvard醫學院和Beth Israel Deaconess醫療中心合作。這項多年計畫包括一項分階段的方法，目的是解決越南和菲律賓這兩個乙型肝炎和丙型肝炎流行率很高的國家的基礎醫療機構的病毒性肝炎診斷和管理障礙。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球E型肝炎診斷測試市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。透過識別市場中「誰的立場」來制定競爭策略。

目錄

第1章 報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 依地區

第2章 市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第3章 競爭格局

  • 主要公司分析
  • Abbott
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Becton, Dickinson, and Co.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • BIOMERIEUX
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第4章 市場細分

  • 依疾病類型分類的全球E型肝炎診斷測試市場
    • 血清學測試
    • 分子測試
    • 免疫測定
    • 現場護理測試
  • 依技術分類的全球E型肝炎診斷測試市場
    • 酵素連結免疫吸附測定法（ELISA）
    • 快速診斷測試（RDT）
    • 新一代定序（NGS）
    • 核酸擴增檢驗（NAAT）
  • 全球E型肝炎診斷測試市場（依最終用戶）
    • 醫院和診所
    • 診斷實驗室
    • 公共衛生機構和研究機構

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章 公司簡介

  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • Diasorin S.p.A.,
  • EKF Diagnostics Holdings plc
  • ELITech Group
  • F. Hoffmann-La Roche Ltd
  • Grifols
  • Hologic, Inc.
  • InBios International, Inc.
  • Mast Group Ltd.
  • QIAGEN GmbH
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
Product Code: OMR2028071

Global Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report by Disease Type (Serology Tests, Molecular Tests, Immunoassays, and Point-of-Care Tests), by Technology (Enzyme-Linked Immunosorbent Assay, Rapid Diagnostic Tests, Next-Generation Sequencing, and Nucleic Acid Amplification Tests) and by End User (Hospitals and Clinics, Diagnostic Laboratories, and Public Health Agencies and Research Institutions), Forecast Period (2024-2031)

The global hepatitis e diagnostic tests market is anticipated to grow at a CAGR of 7.40% during the forecast period (2024-2031). The market's growth is attributed to the demand for global health concern. The global prevalence and significance of Hepatitis E as a major public health concern motivate continued growth and acceptance of diagnostic tests to effectively manage and minimize the disease's impact on public health. According to the National Institute of Health (gov.) in May 2023, the hepatitis E is a liver inflammation caused by the hepatitis E virus (HEV), that is commonly transmitted through contaminated water or the consumption of undercooked animal meat, particularly pork. According to the World Health Organization (WHO), there are approximately 20 million HEV infections annually, resulting in 3.3 million symptomatic cases and 44,000 deaths. This accounts for 3.3% of viral hepatitis-related mortalities. While hepatitis E is prevalent globally.

Segmental Outlook

The global hepatitis E diagnostic tests market is segmented on the product type, animal type, application, and end user. Based on the product type, the market is sub-segmented into stationary multi-slice CT scanner, and portable CT scanner. Based on the animal type, the market is sub-segmented into companion animal, livestock animal, others. Based on the application, the market is sub-segmented into neurology, oncology, cardiology, nephrology, gastroenterology, and others. Furthermore, on the basis of end-user, the market is sub-segmented into veterinary clinics and hospitals, research institutes, and others. The enzyme-linked immunosorbent assay (ELISA) subcategory is expected to capture a significant portion of the market share within the technology segment. The growth can be attributed to the widespread adoption of the procedure to diagnose hepatitis in hospitals.

The Serology Tests Sub-Segment is Anticipated to Hold a Considerable Share of the global Hepatitis E Diagnostic Tests Market

Among the disease type, the serology tests sub-segment is expected to hold a considerable share of the global Hepatitis E Diagnostic Tests market. The segmental growth is attributed to the advancement in serological testing. The introduction of Enzyme Immunoassay (EIA) testing, specifically passive EIA techniques capable of identifying IgM and IgG anti-HEV antibodies, emphasizes technological advances in serology tests for Hepatitis E diagnosis. The division between IgM and IgG antibodies aids in the identification of modern or previous diseases. According to the MDPI, in January 2021, serological tests used to detect HEV infection include enzyme immunoassay (EIA) tests. Indirect EIA assays are capable of detecting IgM and IgG anti-HEV antibodies. IgM anti-HEV antibodies are the first to appear, indicating an acute or recent infection, while IgG anti-HEV antibodies persist for years, suggesting a recent or past infection. However, the sensitivity and specificity of these assays can vary, and there is a potential for cross-reactivity with other viruses such as CMV and EBV. The Wantai test is the most commonly used commercial ELISA test for IgM detection, known for its high sensitivity and specificity among EIA tests.

Regional Outlook

The global hepatitis E diagnostic tests market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing healthcare facilities, a significant amount of applicable manufacturer and rise in government involvement and proficient communities.

The North America Region is Expected to Grow at a Significant CAGR in the global Hepatitis E Diagnostic Tests Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the diagnostic test development across the region. Insights from such studies motivate the development of diagnostic tests capable of identifying numerous markers of Hepatitis E infection, such as antibodies and viral RNA, in order to provide a more complete diagnostic picture and aid in understanding disease dynamics. According to the MDPI, in October 2023, the prevalence of anti-HEV IgG and IgM antibodies, as well as viral RNA, was analyzed in 1002 donor sera in Estonia. Out of these, 48 sera (4.8%) tested positive for anti-HEV antibodies, with 40 (4%) containing anti-HEV IgG and 15 (1.5%) containing anti-HEV IgM. Additionally, 7 donors had antibodies of both classes simultaneously. However, no HEV RNA was detected in any of the blood serum samples. However for a higher incidence of anti-HEV IgG carriers with age, statistical analysis identified no statistically significant associations between infection risk variables and the prevalence of anti-HEV antibodies.

Market Players Outlook

The major companies serving the hepatitis E diagnostic tests market includes Bio-Rad Laboratories, Inc., Danaher Corp., Diasorin S.p.A., EKF Diagnostics Holdings plc, ELITech Group, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2022,Gilead Sciences, Inc. collaborated with Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year program comprises a staged approach to addressing barriers to viral hepatitis diagnosis and management in basic healthcare authorities in Vietnam and the Philippines, two countries with significant hepatitis B and C prevalence.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global hepatitis E diagnostic tests market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Becton, Dickinson, and Co.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. BIOMERIEUX
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Hepatitis E Diagnostic Tests Market by Disease Type
    • 4.1.1. Serology Tests
    • 4.1.2. Molecular Tests
    • 4.1.3. Immunoassays
    • 4.1.4. Point-of-Care Tests
  • 4.2. Global Hepatitis E Diagnostic Tests Market by Technology
    • 4.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 4.2.2. Rapid Diagnostic Tests (RDTs)
    • 4.2.3. Next-Generation Sequencing (NGS)
    • 4.2.4. Nucleic Acid Amplification Tests (NAAT)
  • 4.3. Global Hepatitis E Diagnostic Tests Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Laboratories
    • 4.3.3. Public Health Agencies and Research Institutions

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bio-Rad Laboratories, Inc.
  • 6.2. Danaher Corp.
  • 6.3. Diasorin S.p.A.,
  • 6.4. EKF Diagnostics Holdings plc
  • 6.5. ELITech Group
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. Grifols
  • 6.8. Hologic, Inc.
  • 6.9. InBios International, Inc.
  • 6.10. Mast Group Ltd.
  • 6.11. QIAGEN GmbH
  • 6.12. Siemens Healthineers
  • 6.13. Sysmex
  • 6.14. Thermo Fisher Scientific Inc.
  • 6.15. VWR International, LLC

LIST OF TABLES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 2. GLOBAL SEROLOGY TESTS HYSTEROSCOPE HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 10. GLOBAL OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 16. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 17. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 18. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 19. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 20. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 21. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 22. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 23. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 24. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 25. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 26. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 27. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 28. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 30. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 31. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 32. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY DISEASE TYPE, 2023 VS 2031(%)
  • 2. GLOBAL SEROLOGY TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY TECHNOLOGY, 2023 VS 2031(%)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NEXT-GENERATION SEQUENCING TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 10. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY END USER, 2023 VS 2031(%)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS DIAGNOSTIC LABORATORIES MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 16. US HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. UK HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 27. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)